为了响应国家关于发展人工智能的工作部署，充分应用人工智能技术，提升健康医疗服务水平，加快卫 生健康智能化数字化升级，各地积极推进建设人工智能应用场景，其中，地方发布"人工智能+医疗卫 生"应用场景案例，充分应用人工智能技术，提升互联网医疗服务效率和质量，加快互联网医疗智能化 数字化升级，助力行业高质量发展。 在第三届中国国际供应链促进博览会上，方舟健客（06086.HK）依托其AI应用服务场景、便捷药事服 务等资源，与全球领先的生物制药公司诺和诺德正式签署战略合作备忘录，携手诺和诺德围绕糖尿病和 肥胖症等严重慢性疾病的管理展开项目合作。 战略合作备忘录签署仪式上，谢方敏表示，希望能携手全球生物医药龙头企业诺和诺德，通过探索AI 技术的应用，突破传统健康管理模式中的痛点，为全球控糖管理、体重管理领域提供创新的数智化标杆 方案。 方舟健客创始人、董事长兼首席执行官谢方敏带领企业以科技创新为驱动力，加强与合作伙伴的交流合 作，共同探索行业创新发展新生态。 紧跟行业发展趋势，抓住技术创新机遇 对于人工智能等新技术带来的新发展机遇，方舟健客创始人、董事长兼首席执行官谢方敏指出，自成立 以来，方舟健客深深明白"科技赋能" ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 方舟云康控股有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06086 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 截至 ...

Group 1 - The artificial intelligence industry is undergoing a new round of transformation, with breakthroughs in large model capabilities and a rapid decrease in inference costs driving the swift development of large model applications [1] - Experts at the 2025 Global Digital Economy Conference highlighted that the significant decline in costs over the past year has provided essential foundational conditions for accelerating the implementation of AI applications [1] Group 2 - The internet healthcare sector is experiencing an upgrade opportunity driven by the AI digital wave, focusing on enhancing user experience through intelligent solutions that address user pain points and meet diverse needs [2] - Ark Health has developed the "H2H Smart Healthcare New Ecosystem Service Platform" to improve user service experience, leveraging deep technological expertise and innovative research [2] - The platform has seen a substantial increase in registered users, growing from 42.7 million at the end of 2023 to 49.2 million, with a monthly active user count rising by 20% to 10.1 million [2] Group 3 - AI technology is significantly reshaping industry forms and social life, with China accounting for 42% of the world's "lighthouse factories" and AI medical applications improving early lung cancer screening accuracy to 97% [3] - Ark Health's H2H service platform integrates AI into various application scenarios within internet healthcare, exploring broader possibilities for future industry development [3] - The company has established strategic collaborations with Tencent Cloud and Tencent Health to innovate AI applications in pharmaceutical distribution and health management, enhancing the quality and efficiency of internet healthcare [3]

Core Viewpoint - The strategic partnership between Ark Health (方舟健客) and Novo Nordisk aims to leverage AI technology for the management of chronic diseases such as diabetes and obesity, aligning with China's "Healthy China 2030" initiative and the "Weight Management Year" policy [1][2]. Group 1: Strategic Collaboration - Ark Health and Novo Nordisk signed a strategic cooperation memorandum to collaborate on managing diabetes and obesity through AI and digital health solutions [1]. - The partnership seeks to combine Novo Nordisk's expertise in chronic disease management with Ark Health's AI capabilities to enhance awareness and early intervention in diabetes and obesity [2]. Group 2: Market Demand and Policy Support - The prevalence of diabetes and obesity in China is rising, with over 50% of adults classified as overweight or obese, and approximately 233 million people suffering from diabetes as of 2023, marking a 163% increase since 2005 [3]. - The Chinese government has initiated a three-year "Weight Management Year" action plan, emphasizing the need for digital technology to innovate management models in response to the growing health crisis [4]. Group 3: AI Technology and Industry Growth - The rapid development of generative AI technology is expected to address challenges in medical model training, potentially transforming chronic disease management [4]. - The AI healthcare solutions market is projected to exceed 20 billion yuan by 2025 and reach over 100 billion yuan by 2030, with a compound annual growth rate of 43.2% [4]. Group 4: Service Innovation and Ecosystem Development - Ark Health has established a significant user base and a comprehensive "H2H (Hospital To Home)" smart healthcare platform, enhancing patient experience and operational efficiency [5]. - The company reported a 139% year-on-year increase in adjusted net profit, reaching 17.12 million yuan by the end of 2024, driven by advancements in AI technology [5]. - Ark Health's AI tools provide 24/7 consultation and personalized health services, integrating chronic disease management into a full-cycle health management service [6]. Group 5: Future Outlook - The collaboration aims to create a new ecosystem in diabetes and obesity management, shifting the focus from disease treatment to health promotion, thereby enhancing patient care [6]. - The partnership exemplifies the potential for domestic AI healthcare companies to collaborate with multinational pharmaceutical firms, fostering innovation in the digital transformation of the healthcare industry [6].

Core Insights - Ark Health (方舟健客) has signed a memorandum of cooperation with Novo Nordisk (诺和诺德) to collaborate on managing chronic diseases such as diabetes and obesity [1][3] - The partnership aims to leverage AI technology and digital health solutions to create a comprehensive health management service that transitions from a disease-centered approach to a health-centered approach [3] Group 1 - The collaboration will utilize Novo Nordisk's expertise in diabetes and obesity treatment alongside Ark Health's smart healthcare ecosystem to provide a full-cycle health management service, including medication guidance, reminders, effect tracking, and health education [3] - Ark Health's CEO, Dr. Xie Fangmin, expressed the goal of using AI technology to address pain points in traditional health management models and provide innovative digital solutions for global diabetes and weight management [3] - Novo Nordisk's Senior Vice President, Zhou Xiaping, highlighted the importance of combining chronic disease prevention with digital innovation to enhance awareness and implementation of early screening, diagnosis, and treatment in smart healthcare settings [3] Group 2 - The partnership is expected to explore further innovative collaborations in the healthcare sector during the digital transformation process, benefiting patients with serious chronic diseases and supporting the "Healthy China 2030" strategic goal [3]

Core Insights - Fangzhou Inc. has signed a Memorandum of Understanding with Novo Nordisk to collaborate on managing chronic diseases like diabetes and obesity using AI and innovative healthcare solutions [1][3][4] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 49.2 million registered users and 223,000 physicians as of December 31, 2024 [5] Collaboration Details - The partnership aims to leverage Novo Nordisk's expertise in diabetes and obesity treatment alongside Fangzhou's smart healthcare ecosystem to create a comprehensive health management service [3][4] - The collaboration will focus on medication guidance, reminders, efficacy tracking, and health education, shifting from a "disease-centered" to a "health-centered" model [3][4] Future Goals - Both companies aim to enhance public awareness of diabetes and obesity and implement early screening, diagnosis, and treatment within smart healthcare environments [4] - The partnership is expected to explore further innovative collaborations in the digital transformation of the medical industry, contributing to the "Healthy China 2030" strategic objectives [4]

Core Insights - Ark Health has launched Novo Nordisk's innovative diabetes medications, including the injectable Semaglutide (Nuohe Tai®) and oral Semaglutide (Nuohe Xin®), aiming to provide effective treatment for a broader range of adult type 2 diabetes patients [1] Group 1: Product Launch and Features - Nuohe Tai® is a GLP-1 receptor agonist that has been well-received since its launch in China in 2021 due to its excellent glycemic control and convenient once-weekly dosing [1] - Nuohe Xin®, the world's first oral GLP-1 receptor agonist, was fully launched in China in January 2025, utilizing "SNAC absorption enhancer" technology to facilitate daily oral administration [1] Group 2: Market Context - China has the highest number of type 2 diabetes patients globally, with approximately 148 million patients aged 20-79, accounting for over a quarter of the world's total [1] - The prevalence of overweight/obesity, dyslipidemia, and hypertension is notably high among these patients, indicating a significant health need [1] Group 3: Future Strategy - The company plans to continue integrating digital intelligence with internet healthcare services, establishing strategic partnerships with leading biopharmaceutical companies to create a new landscape for smart healthcare [2] - The goal is to transform cutting-edge medical research into accessible chronic disease management solutions, enhancing service quality for chronic disease patients [2]

Core Viewpoint - Ark Health (06086.HK) has experienced significant stock price fluctuations, with notable increases of nearly 45% on April 15 and 28% on April 16, followed by a 16.22% rise on April 24, indicating strong market interest and trading activity [2][4][6]. Financial Performance - For the fiscal year 2024, Ark Health reported a revenue of 2.707 billion RMB, representing an 11.22% year-over-year growth [4][5]. - The adjusted net profit reached 17.12 million RMB, a substantial increase of 139% compared to the previous year, attributed to enhanced technology and operational efficiency [4][5]. - The gross profit for 2024 was 515.94 million RMB, up from 487.41 million RMB in 2023 [5]. User Engagement and Growth - As of the end of 2024, the platform's registered users increased to 49.2 million, with an average of 10.1 million monthly active users, reflecting a 20% year-over-year growth [4][5]. - The repeat purchase rate among paying users remained strong at 84.7% in 2024 [4]. Market Dynamics - The recent stock price movements are believed to be influenced by the company's positioning within the "AI + healthcare" sector, attracting market capital [6][9]. - Ark Health's integration of the DeepSeek AI platform and the development of the "AI + H2H" (Hospital to Home) healthcare ecosystem have contributed to its market appeal [7]. Shareholder Structure - The shareholding structure is concentrated, with significant holdings by Fangrong Management Limited and associated parties, which may facilitate speculative trading [8]. Capital Market Access - Ark Health was included in the Hong Kong Stock Connect program effective March 10, 2025, enhancing its visibility and access to mainland investors, which likely contributed to increased trading volume and stock price appreciation [9].

Financial Performance - Fangzhou Inc. reported a revenue of RMB 1.2 billion for the fiscal year ending December 31, 2024, representing a year-over-year growth of 25%[2]. - Total revenue for 2024 reached RMB 2,707,368, an increase of 11.2% compared to RMB 2,434,308 in 2023[13]. - Adjusted net profit for 2024 grew significantly by 139% to RMB 17,119 from RMB 7,165 in 2023[16]. - Revenue for the last quarter reached $150 million, representing a 15% increase compared to the previous quarter[93]. - Future guidance indicates a projected revenue growth of 20% for the upcoming fiscal year[93]. - The gross profit margin decreased to 19.1% in 2024 from 20.0% in 2023, while the net loss margin worsened to (31.4)% from (8.1)%[69]. - Total sales cost rose by 12.6% to RMB 2,191.4 million for the year ending December 31, 2024, from RMB 1,946.9 million for the year ended December 31, 2023, aligning with revenue growth[40]. User Engagement and Market Expansion - The company achieved a monthly active user count of 5 million, an increase of 30% compared to the previous year[2]. - Fangzhou Inc. plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[2]. - The company has launched a new telehealth platform, aiming to serve an additional 1 million users by the end of 2025[2]. - As of December 31, 2024, the platform registered users increased to 49.2 million, with an average of 10.1 million monthly active users, reflecting a 20% year-over-year growth[16]. - The company reported a significant increase in user engagement, with a year-over-year growth of 25% in active users[94]. Product Development and Innovation - The company is investing RMB 200 million in new product development, focusing on chronic disease management technologies[2]. - The company is investing $10 million in research and development for innovative health technology solutions[93]. - The company aims to enhance its online chronic disease management market leadership by balancing immediate tactical improvements and long-term strategic planning[28]. - The company plans to optimize its online chronic disease management platform, with a focus on enhancing user experience and conversion rates[191]. Strategic Partnerships and Acquisitions - The company has completed the acquisition of a local healthcare startup for RMB 100 million, enhancing its service offerings[2]. - The company has established strategic partnerships with three major hospitals to enhance its service delivery network[2]. - The company has established strategic partnerships with over 1,500 suppliers and more than 900 pharmaceutical companies, providing nearly 215,000 drug SKUs, with approximately 62% being prescription drug SKUs[26]. - The company has completed a strategic acquisition of a competitor, enhancing its market share by 10%[94]. Governance and Corporate Structure - The board has established three committees to oversee audit, compensation, and nominations, ensuring robust governance[95]. - The company maintains a high standard of corporate governance to protect shareholder interests[93]. - The independent directors provide critical oversight and strategic advice to enhance business development[94]. - The company has adopted a standard code of conduct for directors regarding the trading of company securities, confirming compliance until December 31, 2024[110]. - The audit committee consists of three independent non-executive directors, ensuring oversight of financial reporting and auditor relationships[114]. Financial Position and Assets - Non-current assets as of December 31, 2024, were RMB 55,769, an increase from RMB 54,014 in 2023[14]. - Current assets increased to RMB 608,325 in 2024 from RMB 467,354 in 2023[14]. - Cash and cash equivalents increased to RMB 174.6 million as of December 31, 2024, from RMB 146.3 million as of December 31, 2023, indicating improved liquidity[62]. - As of December 31, 2024, the company's asset-liability ratio was 0.8, down from 4.6 in 2023, indicating improved capital adequacy[81]. Employee and Talent Management - The company has 488 employees as of December 31, 2024, with a diverse distribution across various functions[80]. - The company will focus on recruiting top talent in AI, healthcare, chronic disease management, and the pharmaceutical industry to support ongoing growth[32]. - The total salary cost for the year ended December 31, 2024, was RMB 883.3 million, significantly up from RMB 147.0 million for the year ended December 31, 2023, mainly due to expenses from the restricted share unit plan[79]. Risk Management and Internal Controls - The company has implemented strict risk management and internal control policies to continuously improve its operational effectiveness and mitigate potential risks[149]. - The audit department leads the company's risk management efforts, assessing strategic, operational, and financial risks, and providing management solutions[150]. - The company has established a mechanism for handling and disclosing insider information, ensuring compliance with relevant regulations[162]. Community Engagement and Corporate Responsibility - The company made charitable donations totaling RMB 0.3 million in 2024[181]. - The company emphasizes sustainable development and environmental responsibility through various energy-saving measures[193]. - The company maintains strong relationships with stakeholders, including customers, suppliers, employees, and shareholders, to ensure long-term success[195][196][197][198].

Core Insights - The company, Ark Health, reported a total revenue of 2.707 billion yuan for 2024, marking an 11.2% year-on-year increase, and an adjusted net profit of 17.119 million yuan, which is a 139% increase compared to 2023, showcasing its enhanced profitability and the effectiveness of AI in the healthcare sector [3][4] - Ark Health focuses on internet-based chronic disease management, providing comprehensive services and has successfully listed on the Hong Kong Stock Exchange, boosting market confidence in the internet and pharmaceutical industries [3][4] - The company aims to maintain high-quality development by leveraging AI technology and innovation, particularly in the Guangdong-Hong Kong-Macao Greater Bay Area [3][4] Financial Performance - Online retail pharmacy services contributed 1.405 billion yuan in revenue, up 8.3%, while customized content and marketing solutions generated 105 million yuan, with a growth rate of 20.7% [4] - The gross margin for comprehensive medical services improved from 15.20% at the end of 2023 to 17.20% at the end of 2024, indicating a focus on sustainable business development [4] - The registered user base for the chronic disease management service platform grew from 42.7 million to 49.2 million, with a monthly active user count rising to 10.1 million, reflecting a 20% year-on-year increase [4][5] Technological Advancements - The company has integrated advanced technologies such as large language models, big data, and cloud computing to enhance its service offerings, including AI doctor assistants and AI customer service assistants [6][7] - The AI doctor assistant can handle over 80% of repetitive inquiries, allowing doctors to focus on complex cases, thereby improving service efficiency and reducing costs [6][7] - The integration of the DeepSeek model and proprietary technology has created a closed-loop service system from hospitals to homes, enhancing the overall healthcare value chain [6][7] Market Position and Strategy - Ark Health has established partnerships with over 1,500 suppliers and 900 pharmaceutical companies, offering approximately 215,000 drug SKUs, with 62% being prescription drugs [4][5] - The company is positioned to strengthen its leading market position in online chronic disease management through strategic initiatives and continuous optimization of its operational tactics [5][6] - The integration of its service platform with medical insurance payment systems has improved user retention and reduced financial burdens on patients, further solidifying its market position [8][9] Industry Impact - The recent inclusion of Ark Health in the Hong Kong Stock Connect is expected to attract more mainland investors, potentially enhancing liquidity and valuation [8] - The company's growth reflects its competitive strength in the internet healthcare sector and contributes to the high-quality development of the biopharmaceutical industry in Guangdong [9] - The supportive policies from the National Health Commission regarding AI applications in healthcare signal a positive outlook for the internet healthcare industry, encouraging further innovation [9]